2023 A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1 and chemotherapy, in first-line treatment of 60 patients with relapsed/metastatic head and neck squamous cell carcinoma.
2023 A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1 and chemotherapy, in 75 patients with relapsed/metastatic esophageal squamous cell carcinoma.
2023 Endpoints News: Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise
2023 Developing Novel Checkpoint Inhibitors Against Bladder Cancer
2022 Our new study was covered by 64 news outlets worldwide
2022 GEN: First-In-Class Immune Checkpoint Therapy Unlocks NK Cell Attack on Tumors
2022 Les résultats de la recherche pourraient renforcer l’efficacité de la thérapie par points de contrôle immunitaire
2022 Cancro: promettente nuova terapia sviluppata dall’Albert Einstein College of Medicine
2022 Πολλά υποσχόμενη νέα θεραπεία για τον καρκίνο που αναπτύχθηκε από το Κολέγιο Ιατρικής Albert Einstein
2022 El Confidencial: Las nuevas 'células asesinas' contra el cáncer que pueden cambiarlo todo
2022 Einstein Researchers Develop Promising New Cancer Therapy
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-L1, to treat 115 patients with non-small cell lung cancer.
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-L1, to treat 55 patients with small cell lung cancer.
2022 New immune checkpoint inhibitor TQB2618 from our lab started a phase 2 clinical trial to treat 110 patients with recurrent/metastatic nasopharyngeal carcinoma who had failed previous platinum-based chemotherapy and immune checkpoint inhibitors (PD-1/PD-L1, etc.).
2022 A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1, to treat 90 patients with relapsed and refractory lymphoma.
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with demethylation drugs (Azacitidine, Decitabine), to treat 70 patients with recurrent/refractory acute myeloid leukemia (AML), myelodysplastic syndromes (MDS).
2022 A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-1, to treat 50 patients with advanced melanoma.
2022 Patent [Antagonist Monoclonal Antibodies against Human Immune Checkpoint CEACAM1 (CD66a) and Formulations, Kits, and Methods of Use Thereof] was granted.
2022 Montefiore Einstein Cancer Center Researchers Receive Price Family Foundation Health Equity Research Awards.
2022 Overcoming Resistance to Checkpoint Inhibitor Cancer Therapy.
2022 Checkpoint Protein's Unexpected Role in Fat Metabolism.
2022 Patent was granted.
2021 肿瘤免疫学家臧星星教授: 站在世界药物研发最前列, 展望KIR3DL3-HHLA2新免疫检查点
2021 Promising New Cancer Immunotherapy Drug.
2021 Freeing Immune Cells to Combat Cancer.
2020 A novel immune checkpoint inhibitor derived from our lab started clinical trial to treat 50 cancer patients with advanced solid tumors who had failed standard treatments or lack effective treatments.
2020 Cancer Research Institute CLIP Investigator.
2020 Patent (B7x and Its Derivatives for Treating and Preventing Cardiovascular Disease) was granted.
2019 A new drug company is established based on our research: NextPoint Therapeutics.
2019 MD-PhD student Peter John wins Lasker Essay Contest.
2019 Patent (TMIGD2 and Its Derivatives as Blockers or Binders of Cancer-expressed HHLA2 for Immunotherapies) was granted.
2019 MD/PhD Candidate Makes His Mark on Cancer Research and Bronx Kids' Program.
2018 Patent (HHLA2 as a Novel Inhibitor of Human Immune System and Uses Thereof) was granted.
2018 MD-PhD student Peter John received F30 Individual Predoctoral Fellowship Award from National Institutes of Health.
2017 Our new immunotherapy technologies were licensed to a biopharmaceutical company in California.
2017 A new pharmaceutical company was established based on our research.
2017 The Zang lab/Einstein and Chia Tai Tianqing Pharmaceutical Group signed an agreement to develop new immunotherapy drugs.
2016 Patent (Antibodies to Human B7x for Treatment of Cancer. Inventors: XingxingZang, James P. Allison) was granted.
2016 MD-PhD student Jordan Chinai received the first Barry R. Bloom Speaker Award.
2016 The Zang lab/Einstein and Jiangsu Hengrui Medicine Co signed an agreement to develop novel immunotherapy for human diseases.
2015 Xingxing Zang received Lustgarten-eBioscience Memorial Award, American Association of Immunologists.
2015 The Zang lab and Pfizer to jointly develop novel drugs for treating human cancers.
2015 Congressionally Directed Medical Research Programs.
2014 MD-PhD student Kim Ohaegbulam received NRSA F31 Individual Predoctoral Fellowship Award from National Institutes of Health.
2014 Hitting Them with Her Best Shot: An Einstein Alum Talks to Kids about Vaccines.
2013 Our new cancer immunotherapy technology was licensed to a pharmaceutical company.
2013 MD-PhD student Kim Ohaegbulam was invited as a Keynote Speaker for the Annual Moffitt Student Research Day at the Moffitt Cancer Center, Florida.
2013 Regulating Human Immune Response
2008 Xingxing Zang received NIH Director’s New Innovator Award (NIH Type 1 Diabetes Pathfinder Award).